NCT02082899View on ClinicalTrials.gov

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Active Comparator EBI-005 5 mg/mL

DRUG

Placebo Comparator

Trial Locations (1)

L4W 1A2

Investigation Site, Mississauga

Sponsors
All Listed Sponsors
lead

Eleven Biotherapeutics

INDUSTRY